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Abstract
Objective—Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately 
present disease progression. Molecular mechanisms underlying acquired resistance are still 
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unknown. Herein, we characterise the role of tumour-initiating cells (T-ICs) and signalling 
pathways involved in sorafenib resistance.
Design—HCC xenograft mice treated with sorafenib (n=22) were explored for responsiveness 
(n=5) and acquired resistance (n=17). Mechanism of acquired resistance were assessed by: (1) role 
of T-ICs by in vitro sphere formation and in vivo tumourigenesis assays using NOD/SCID mice, 
(2) activation of alternative signalling pathways and (3) efficacy of anti-FGF and anti-IGF drugs in 
experimental models. Gene expression (microarray, quantitative real-time PCR (qRT-PCR)) and 
protein analyses (immunohistochemistry, western blot) were conducted. A novel gene signature of 
sorafenib resistance was generated and tested in two independent cohorts.
Results—Sorafenib-acquired resistant tumours showed significant enrichment of T-ICs (164 
cells needed to create a tumour) versus sorafenib-sensitive tumours (13 400 cells) and non-treated 
tumours (1292 cells), p<0.001. Tumours with sorafenib-acquired resistance were enriched with 
insulin-like growth factor (IGF) and fibroblast growth factor (FGF) signalling cascades (false 
discovery rate (FDR)<0.05). In vitro, cells derived from sorafenib-acquired resistant tumours and 
two sorafenibresistant HCC cell lines were responsive to IGF or FGF inhibition. In vivo, FGF 
blockade delayed tumour growth and improved survival in sorafenib-resistant tumours. A 
sorafenib-resistance 175 gene signature was characterised by enrichment of progenitor cell 
features, aggressive tumorous traits and predicted poor survival in two cohorts (n=442 patients 
with HCC).
Conclusions—Acquired resistance to sorafenib is driven by T-ICs with enrichment of progenitor 
markers and activation of IGF and FGF signalling. Inhibition of these pathways would benefit a 
subset of patients after sorafenib progression.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a major health problem, being currently the third cause 
of cancerrelated death worldwide.1 Most patients are diagnosed when the metastatic process 
is already present. In these cases, the multitarget tyrosine kinase inhibitor (TKI) sorafenib is 
the only Food and Drug Administration (FDA)-approved systemic therapy, expanding 
patient median survival from 7.9 to 10.7 months.2 Despite initial response, most patients 
develop disease progression. In the case of HCC, radiological progression under sorafenib 
occurs after 4–5 months of treatment.2 As sorafenib targets several signalling pathways, 
acquisition of resistance might involve different mechanisms, including the activation of 
compensatory signalling cascades, rather than specific DNA aberrations, as was described 
with BCR-ABL and imatinib3 and BRAF mutations in melanomas resistant to vemurafenib.4 
As the precise molecular mechanisms underlying resistance to sorafenib are still barely 
understood,56 there is an urgent need to characterise drivers of resistance to identify ideal 
targets for second-line therapies.
Many solid tumours, including HCC, contain a small subpopulation of cells bearing 
progenitor cell-like features, termed cancer stem cells (CSC) or tumour-initiating cells (T-
ICs).7 A growing number of studies using human samples and preclinical models suggest 
that T-ICs are responsible for tumour relapse, metastasis and chemoresistance to antitumour 
drugs leading to disease progression and mortality.7 Thus, therapeutic strategies aimed to 
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target T-ICs are particularly attractive as they could circumvent, at least partially, the 
development of resistance.
In the present study, we explored the mechanisms underlying acquisition of resistance to 
sorafenib in an animal model of HCC. Resistant tumours had enrichment of T-ICs, which 
showed enhanced tumourigenicity when transplanted in NOD/SCID mice. Transcriptomic 
analysis revealed that activation of IGF and FGF pathways contributes to the development of 
this resistance and that it could be overcome with selective inhibitors. Finally, we proposed a 
gene signature derived from sorafenib-resistant tumours with prognostic value in patients 
with HCC.
MATERIAL AND METHODS
Establishment of a HCC xenograft model of acquired resistance to sorafenib
Subcutaneous Huh7 cells-derived tumours treated with sorafenib (30 mg/kg/day)8 for 4 
weeks were excised in small pieces and engrafted in nude Balb/C mice (n=35). When 
tumours reached 100 mm3 volume, mice were treated with sorafenib (n=26) or placebo 
(n=5). Upon development of acquired resistance (see online supplementary material and 
methods), animals were used to explore T-ICs enrichment (n=5) or randomised to receive 
either anti-FGF therapy (brivanib, 100 mg/kg/day, n=6)9 or be maintained on sorafenib 
(n=6). Tumours exhibiting slow growth rate (ratio <1.3; tumour volume day 3/tumour 
volume day 1) or regression were considered sorafenib-sensitive. Four mice were excluded 
due to lack of response to sorafenib. We defined survival as the time comprised between 
randomisation and euthanasia. According to institutional ethical guidelines, mice were 
euthanised when tumours reached 10% body weight (~2000 mm3) or mice showed 
discomfort, as shown by significant body weight loss. One hour after the last dose of 
treatment, animals were euthanised, and tumours collected and cut into portions to isolate 
cells, fixed for immunohistochemical analysis or frozen for mRNA and protein analysis.
Sphere formation assay
At least three subcutaneous Huh7-derived tumours corresponding to each experimental 
group, sorafenib-resistant, sorafenibsensitive and non-treated control group, were excised 
and subjected to isolation and spheroid assays as previously described.10 For more details 
see online supplementary materials and methods section.
Tumour-initiating capacity
Tumour-initiating capacity was performed as previously described.7 Briefly, limiting 
dilutions (102, 103 and 104) of cells were injected subcutaneously into the flanks of NOD. 
Cg-Prkdcscid IL2rgtm1Wjl (NSG) mice in a mixture (1:1) of 1×PBS and Matrigel (BD 
Biosciences). Tumour incidence (number of tumours per number of injections) and tumour 
latency (time from injection to first tumour palpability) were assessed weekly. Tumours 
were confirmed on histology. If a tumour was palpable at a single injection site, it was 
removed surgically to allow continued evaluation of other injection sites. Mice were 
assessed for up to 36 weeks, and animals with no sign of tumour formation were examined 
at necropsy for confirmation.
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Reagents, cell culture conditions, siRNA transfection, immunohistochemical analysis, and 
western blot analysis
See online supplementary materials and methods section.
Human samples
A total of 442 HCCs (87.5% early stages, Barcelona clinic liver cancer (BCLC) 0/A) 
collected from patients undergoing resection at three hospitals of the HCC Genomic 
Consortium (Hospital Clínic, Barcelona; Mount Sinai, New York and National Cancer 
Institute, Milan) were included in the study. These samples, with complete annotated clinical 
data and follow-up, have been used in previous studies conducted by the HCC Genomic 
Consortium.11–15 A first set, Cohort A, included 223 HCCs (45% hepatitis C virus (HCV), 
20% HBV and 35% other aetiologies) and a second independent set, Cohort B, included 219 
HCCs (61% HCV, 21% HBV and 18 other aetiologies). Online supplementary table S1 
presents the main clinicopathological features of the patients included in the study.
Gene expression analysis profiling
For microarray profiling of mice xenografts and tumour-derived spheres, RNA isolation, 
cDNA transcription and mRNA processing were done as previously described.1215 For more 
details, see online supplementary materials and methods section.
Bioinformatic and statistical analysis
See online supplementary materials and methods section.
RESULTS
Acquired resistance developed after long-term exposure to Sorafenib
To study acquired resistance to sorafenib, we generated an in vivo xenograft mouse model 
(figure 1A). Tumour monitoring revealed that 65% of mice (17/26) developed acquired 
resistance after a median of 42 days (p25–p75, percentiles: 33–49), defined by ≥30% 
increase in tumour volume in 3 days in tumours that had showed response to sorafenib for 
>15 days (figure 1B). Among the remaining nine animals, four (15%) were excluded from 
the study, since no response was observed during the first 15 days of treatment, and five 
animals (19%) were defined as long-term responders harbouring sensitive tumours. Tumour 
growth slopes of acquired resistant and sensitive tumours for the 4 weeks prior to 
development of resistance show a sharp increase in tumour volume (figure 1C).
Genomic profiling reveals a role of IGF and FGF signalling in sorafenib-acquired 
resistance
Microarray gene expression analysis was used to unravel molecular mechanisms underlying 
acquired resistance to sorafenib in the tumours of the experimental mouse model. We found 
528 genes differentially expressed between acquired resistant and sensitive tumours (>1.5-
fold, p<0.05, figure 2A, see online supplementary tables S3 and S4). Gene ontology and 
ingenuity pathways analysis (IPA) software mapped these genes to several functions and 
regulatory networks; 170 overexpressed genes in acquired resistant tumours were mostly 
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involved in cell cycle progression, proliferation, migration and apoptosis (ie, IGF1R, 
FGFR1, FGF18, MYC, PDGFD, TGFBR2, PIK3C2G, MMP16) and mediators of cellular 
adhesion (ie, VCAN, FN1, SLC7A11, LAMA4). Conversely, 358 downregulated genes were 
mainly implicated in liver development and differentiation. The main networks associated 
with acquired resistance were those involving IGF1R, PI3K, MYC and FGFR1 activation 
(figure 2B).
Sorafenib-acquired resistant tumours were enriched with gene signatures of poor prognosis 
in liver cancer,16 activation of proliferative pathways,12 a signature of IGF1R activation in 
HCC,17 mTOR complex 1 (mTORC1) activation, induction of HIF-1α target genes and 
embryonic stem/progenitor cell origin (FDR<0.05) reported in MSigDatabase (see figure 2C 
and online supplementary table S5). Interestingly, they were also associated with gene sets 
of acquired resistance to antitumour therapies in multiple tumour types, including 
chemotherapy and tyrosine kinase inhibitors (TKIs). By contrast, sorafenib-sensitive 
tumours were enriched in gene signatures of hepatic differentiation,18 cell adhesion, 
inflammatory response and better outcome, suggesting preservation of the liver function (see 
online supplementary table S6).
Sorafenib-acquired resistant tumours are enriched in T-Ics
Transcriptomic analysis revealed an enrichment of progenitor cell features in tumours 
resistant to sorafenib (see figure 2C and online supplementary table S5). Thus, we 
hypothesised that these tumours could contain features of CSC or T-ICs. These cells are 
mainly responsible of tumour progression as described in other malignancies,7 being 
characterised by having selfrenewal potential and the ability to initiate tumours once 
transplanted into immunodeficient mice. For this purpose, we first evaluated the capacity of 
cells isolated from xenograft tumours to generate spheroids in limiting dilution assays under 
nonattached culture conditions. Results showed that cells from sorafenib-acquired resistant 
tumours generated spheres at higher frequency (1 sphere for 65 cells (95% CI 41 to 102)) 
than those derived from sensitive (1 for 7850 (95% CI 4967 to 12 409)) or non-treated 
tumours (1 for 139 (95% CI 83 to 232)) p<0.05 (figure 3A). After dissociation of these 
spheres into single suspension, sphere-forming cells from acquired resistant tumours gave 
rise to secondary spheroids with high efficiency (data not shown).
Next, we confirmed that sorafenib-acquired resistant tumours were enriched with T-ICs in 
vivo by performing serial transplant limiting dilutional tumourigenicity assays into NOD/
SCID mice. Subcutaneous injection of as few as 102 sorafenib-acquired resistant tumour 
cells induced tumours in 100% of the mice, whereas only 12.5% of mice developed tumours 
from non-treated tumour cells, and no tumours developed from sensitive tumour cells. The 
frequency of T-ICs in acquired resistance, parental and sensitive to sorafenib was 1/164 
(95% CI 71 to 376), 1/1292 (95% CI 775 to 2153) and 1/3400 cells (95% CI 7911 to 22 
695), respectively (figure 3B). Taken together, these data suggest a significant enrichment of 
T-ICs in HCCs with acquired resistance to sorafenib.
We further confirmed that spheres from sorafenib-acquired resistant tumours had enhanced 
expression of several liver progenitor markers19 epithelial cell adhesion molecule (EpCAM), 
CD133/PROM-1, CD90/THY-1, the epithelial progenitor marker CK19 and the epithelial–
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mesenchymal transition (EMT) protein vimentin compared with spheres from non-treated 
tumours (see figure 3C and online supplementary figure S1A). Growing in adherent 
conditions, the expression of some of these markers was still higher in cells from sorafenib-
acquired resistant tumors than in parental non-treated cells (see figure 3D and online 
supplementary figure S1A).
Cells isolated from sorafenib-acquired resistant tumours have activation of pathways 
involved in tumour progression and survival
To better understand the signalling pathways deregulated in T-ICs in sorafenib-acquired 
resistant tumours, we conducted a microarray gene expression profile analysis. A total of 
342 wellannotated genes were differentially expressed (≥1.5-fold, FDR <0.05) between 
sorafenib-acquired resistant and parental nontreated cells growing under sphere formation 
conditions (see figure 4A and online supplementary tables S7 and S8). GSEA showed that 
spheres derived from sorafenib-acquired resistant tumours were particularly enriched in gene 
signatures related to stem cell/progenitor features in the liver (ie, CK19 signature,14 
EpCAM20 and hepatoblastoma-C2,21 http://www.broadinstitute.org/msigdb, FDR<0.05, 
figure 4A). Moreover, there was a clear enrichment for gene sets related to pathways 
essential for tumour development and cell survival (ie, IGF1R signalling,17 mTOR 
signalling) and biological functions involved in cell death and survival, cellular movement or 
embryonic development (see figure 4A and online supplementary table S8).
Considering the genomic data obtained in our xenograft tumour model (figure 2B, C), 
increased expression/activation of IGF1R and FGFR1 was confirmed in cells derived from 
sorafenib-acquired resistant tumours in comparison with parental non-treated cells (figure 
4C), as well as increased activity of downstream protein kinase B (AKT) signalling. We also 
confirmed that cells from sorafenib-resistant tumours had increased cell viability with 
respect to parental cells when cultured with sorafenib (5 μM) for 72 h (64% vs 48%, p=0.01; 
figure 4B).
Next, we tested the effects of specific IGF and FGF inhibition in spheres derived from 
resistant tumours. Using siRNA, IGF1R and FGFR1 expressions were downregulated in 
cells derived from sorafenib-acquired resistant tumour and parental cells (see online 
supplementary figure S2A, B). However, siRNA against IGF1R or FGFR1 did not 
significantly decreased cell viability when used as single agents and only achieved 
significant decrease in viability when combined with sorafenib (3 μM; figure 4D). 
Conversely, when using linsitinib (5 μM), a dual TKI of IGF1R/IR, and the pan-FGFR 
inhibitor BGJ398, a significant decrease in cell viability was obtained (figure 4E). We 
speculate that these suboptimal outcomes when using siRNA are, in part, the result of the 
modest knockdown efficiency obtained in acquired resistant cells compared with parental 
cells (see online supplementary figure S2A). Then, we explored the mechanism of resistance 
in two sorafenib-resistant cell lines derived from Hep3B and Huh6 cells (figure 5). Western 
blot analysis showed that Huh6 had activation of IGF1R and downstream AKT (figure 5A 
left panel), while Hep3B, that was previously reported to mediate resistance to sorafenib 
through epidermal growth factor receptor (EGFR) activation,22 showed increased 
upregulation of FGFR1 expression/activation but not of IGF1R signalling (figure 5B, left 
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panel). In consequence, IGF1R inhibitor linsitinib had stronger efficacy in reducing cell 
viability in Huh6-resistant cells than in parental cells (78% vs 92%, p=0.04) (figure 5A). 
Finally, in agreement with our observations in cells from sorafenib-resistant tumours, 
Hep3B-resistant and Huh6-resistant cell lines had increased expression of several progenitor 
cell markers (see online supplementary figure S1A and B).
Other previously described mechanisms of acquired resistance to sorafenib, such as 
increased Mitogen-Activated Protein Kinase 14 (MAPK14) activation5 (as measured by 
pMAPK14), where not observed in neither our in vivo and in vitro models nor the two 
additional cell lines resistant to sorafenib (see online supplementary figure S2C). 
Furthermore, GSEA analysis comparing the gene expression profile of sorafenib-acquired 
resistant and sensitive tumours showed no enrichment of p38/MAPK14 pathway gene set 
(data not shown).
Anti-FGF therapy reverts resistance and induces liver-specific functions in sorafenib-
acquired resistant tumours
Upon development of resistance, mice were randomly assigned to continue to receive a 
FGFR inhibitor (brivanib, 100 mg/kg/day, figure 1A) or continue on sorafenib. Brivanib 
induced a significant delay of tumour growth (day 12: 1141±424 vs 1659 ±264 mm3 in 
sorafenib-treated animals, p=0.03, figure 6A), also showing a trend to increased survival, 
from a median of 14 days (95% CI 12 to 16) in sorafenib-treated animals up to 32 days 
(95% CI 5 to 59) in mice receiving brivanib (p=0.07, figure 6B). No significant treatment-
related side effects were observed.
Quantitative real-time PCR analysis confirmed significant higher expression of IGF1R (2.1-
fold, p=0.021) and FGFR1 (4.1-fold, p=0.015) in sorafenib-acquired resistant tumours 
compared with sensitive tumours (figure 6C), as detected by microarray analysis, whereas 
brivanib treatment reduced FGFR1 expression (2.4-fold, p=0.007). On the other hand, no 
changes of other proangiogenic factors, such as vascular endothelial growth factor 
(VEGFA), FGF1, FGF2, IL8 and ANGT2 (see online supplementary figure S3) were found. 
Immunohistochemical analysis further confirmed increased FGFR1 and IGF1R protein 
expression in sorafenib-acquired resistance (see online supplementary figure S4) and, 
importantly, a notable enhanced activation of these receptors and downstream activation of 
p-Extracellular Signal-regulated Kinase-1 (ERK) and p-RPS6, surrogates of Ras-MAPK and 
PI3K-Akt-mTOR signalling activation, respectively (figure 6D). Furthermore, brivanib 
treatment decreased FGFR1 activation, as well as ERK and p-RPS6 effectors (figure 6D), 
supporting that the development of acquired resistance involves signals triggered by IGF1R 
and FGFR1 activation.
Moreover, transcriptomic analysis of tumours treated with the FGFR inhibitor versus those 
following on sorafenib after randomisation revealed that brivanib induced differential 
expression of 180 genes, including inhibitors of proliferation, as well as regulators of FGF 
signalling (ie, FGF18, FGFR1OP FRLT3, HRASLS, SPRY2; greater than twofold, p<0.05, 
see online supplementary table S9). GSEA further showed reversion of genomic traits of 
proliferation and tumour progression and enrichment of liver-specific functions after 
treatment with brivanib (see online supplementary table S10).
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A gene signature of resistance to sorafenib is associated with poor outcome in patients 
with HCC
Genomic profiling of sorafenib resistance and sensitive mice xenografts enabled us to 
generate a 175-gene signature of sorafenib resistance (FDR<0.20) (see figure 7A and online 
supplementary table S11). Due to the lack of genomic information from biopsies derived 
from patients treated with sorafenib, prediction class was performed in two independent 
cohorts of surgically resected patients, cohort A (n=223) and cohort B (n=219), whose gene 
expression profiles had been previously analysed.11–15 Prediction analysis showed that 16% 
and 12% of patients harboured the gene signature in cohort A and cohort B, respectively.
Next, we evaluated the prognostic performance of the gene signature of resistance and 
showed that it was able to identify a subset of patients with HCC with worse prognosis after 
resection (median survival: 4.1 vs 5.6 years (p=0.046), and 3.1 vs 9.5 years (p=0.002; figure 
7B, C), in both independent cohorts. Patients harbouring the signature had significantly 
more advanced tumours (BCLC-B/C stage, p=0.043), vascular invasion (p<0.001), tumour 
satellites (p=0.02) and enrichment with signatures of poor prognosis (EpCAM, CK19), 
proliferation class (FDR<0.05) and those identifying patients with HCC with IGF1R and 
Notch signalling activation (p<0.05; see online supplementary table S12).
DISCUSSION
In the present study, we demonstrated that acquired resistance to sorafenib, the unique 
effective therapy for advanced HCC, is characterised by novel molecular features and 
observations including: (1) clear enrichment in T-ICs with progenitor cell features, (2) 
activation of signalling cascades essential for growth and survival, such as IGF, FGF, Myc 
and PI3K, not activated in sensitive tumours, (3) resistance can be overcome with inhibitors 
of these pathways and (4) the genomic characterisation of acquired resistant tumours 
identify a gene signature linked to poor prognosis.
During the last decade, a particular emphasis has been made on resistance to kinase 
inhibitors in the context of tumour dependency or oncogenic addiction. In this scenario, the 
most common traits of acquired resistance mechanisms are the persistent activation of the 
oncogenic target itself or its downstream signaling pathways due to secondary mutations in 
the target kinase (e.g. EGFR (T790M) in gefitinib/erlotinib-resistant non small-cell lung 
carcinoma (NSCLC) patients,23 or in TSC2 in a tumor treated with everolimus in anaplastic 
thyroid) or to increased gene dosage (e.g. BCR-ABL amplifications in imatinib-resistant 
CML patients).24 Alternatively, deregulation of feedback loops, such as the case of PI3K/
AKTactivation by mTOR or MEK inhibitors,2526 has been proposed as mediators to escape 
from drug pressure. In addition to these wellestablished mechanisms, pathway-independent 
resistance mechanisms, such as acquisition of stem/progenitor cell phenotype, within the 
heterogeneous tumour cell population have also been suggested. 7 This later model 
constitutes an attractive framework to understand the onset of acquired resistance, 
considering that treatment-resistant initiating cells present self-renewal capacities required 
for disease survival and dissemination.
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The identification of key molecular events responsible for the acquisition of resistance to 
sorafenib is particularly challenging due to: (1) the high molecular heterogeneity of HCC, 
(2) the multiple potential drivers but no clear oncogenic addiction loops and (3) the limited 
understanding of the mechanisms of action of sorafenib. Recent reports have attempted to 
unveil the complex mechanisms that underlie the development of resistance to sorafenib, the 
unique effective therapy for advanced HCC, including crosstalks of PI3 K/Akt27 and JAK-
STAT signalling, hypoxia-inducible pathways6 and epithelial to mesenchymal transition 
events28 or Mapk14-dependent activation of Mek-Erk and Atf2 signalling.5 In line with our 
findings, a previous study suggested that in vitro long-term exposure to sorafenib induced 
the generation of a population of cells with increased expression of progenitor cell markers 
and enhanced migratory and invasive abilities.28
The broad spectrum of activity of sorafenib suggests a complex plethora of events 
contributing to the development of acquired resistance. In our mouse model, the mechanisms 
that ultimately leads to upregulation of IGF1R and/or FGFR1 could involve, among others, 
miRNA or epigenetic regulation followed by clonal selection.29 Nonetheless, no evidence of 
other recently reported mechanism of resistance was observed (ie, EGFR signalling 
upregulation or MAPK14 activation.52230 This highlights the functional redundancy of 
diverse TK signalling pathways involved in the acquisition of resistance.
We previously reported that IGF signalling is activated in 20% of early HCC, and can be 
efficiently inhibited in preclinical models.17 Similarly to our data, increasing evidence 
strongly suggests an important role of IGF and FGF signalling in conferring drug resistance 
in human malignancies,2931 including a study that highlighted the role of IGF1R in CSC 
biology within the liver.32 This signalling cascade has been identified as a promoter of cell 
proliferation and survival in the context of chronic exposure to EGFR and BRAF inhibitors 
and chemotherapy in several malignancies.33 34 Our data support exploring IGF TKI in HCC 
as second-line therapy. The fact that monoclonal antibodies against IGF1R, where not 
effective in front line, does not undermine the potential therapeutic use of TKI after 
progression to sorafenib, since there is a relevant activation of IGF pathway in this setting 
and the mechanism of action of small molecules simultaneously block both IGF1R and 
insulin receptor (IR).
FGF signalling has a central role in tumour progression, angiogenesis and has emerged as a 
driver of resistance.31 In the current study, we observed a positive effect of FGF inhibition in 
experimental models of acquired resistance to sorafenib results that were consistent with 
pancreatic neuroendocrine tumours with acquired resistance to sorafenib.35 Unfortunately, 
this effect has not been confirmed in a phase III trial in second line in HCC.36
In conclusion, the experimental study reported herein points to IGF and FGF signalling as 
relevant activated axis partially responsible of acquired resistance to sorafenib therapy in 
HCC. Further understanding of these mechanisms will allow the design of phase II–III 
studies using biomarker-based trial enrichment where samples can be obtained before and 
after treatment. Collecting tissue samples in all HCC clinical trials has emerged as a critical 
recommendation in the recent Guidelines of Management of HCC.37 This approach would 
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allow us to further understand the mechanisms of sorafenib resistance and also guide trial 
enrichment and personalised/stratified oncotherapeutics.
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Significance of this study
What is already known on this subject?
• The multitarget tyrosine kinase inhibitor (TKI) sorafenib is the unique Food 
and Drug Administration (FDA)-approved therapy for patients with advanced 
hepatocellular carcinoma (HCC). However, despite favourable initial 
response, most patients develop disease progression. There is no effective 
second-line therapy approved for these patients.
• The mechanisms underlying resistance to sorafenib are complex and not 
clearly elucidated. They may include compensatory activation of signalling 
pathways, acquired mutations and epithelial to mesenchymal transition events 
among others.
• Cancer stem cells have been proposed as key mediators of resistance to 
antitumour therapies in solid malignancies.
What are the new findings?
• Long-term exposure to sorafenib induces HCC tumours with enrichment of 
tumour-initiating cells (T-ICs) with progenitor/stem cell features.
• Acquired resistance to sorafenib is led by the activation of two major 
signalling axes essential for tumour growth and survival, FGF and IGF 
signalling. Specific inhibition of these pathways can overcome resistance in 
vivo and reduce viability of cells derived from acquired resistant tumours and 
sorafenib-resistant cell lines.
• Genomic characterisation of tumours that develop acquired resistance allowed 
us to propose a gene signature, which is linked to poor prognosis.
How might it impact on clinical practice in the foreseeable future?
• Our study provides experimental evidence of potential mechanisms 
underlying resistance to sorafenib. Eventually, these findings will contribute 
to the optimal design of clinical trials to evaluate new drugs blocking IGF and 
FGF pathways in HCC in second-line treatment, a current unmet medical 
need.
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Acquired resistance to sorafenib therapy in an in vivo model of hepatocellular carcinoma 
(HCC). (A) Experimental design of a HCC xenograft model of acquired resistance to 
sorafenib. (B) tumour growth reveals three patterns of growth in 26 animals: primary 
resistance, acquired resistance and long-term responsiveness. Acquired resistance developed 
after a 30% increase in tumour volume in animals responsive to sorafenib for at least 15 
days. Significant statistical differences (*) were observed in sorafenib-resistant and sensitive 
tumour volumes in all time points in between. (C) Tumour growth evolution for 28 days 
prior to development of acquired resistance. Significant statistical differences (*) were 
observed in all time. Plotted data are expressed as mean and SDs of tumour volume.
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Identification of mechanisms underlying acquired resistance to sorafenib. (A) Heat map 
showing 528 differentially expressed genes in sorafenib-acquired resistant (n=4) and 
sensitive tumours (n=3; >1.5-fold, p<0.05). The highest upregulated (red) and 
downregulated (green) genes in sorafenib-acquired resistant tumours are listed. (B) Top two 
rated networks generated by Ingenuity pathway analysis reflecting transcriptomic changes 
after acquired resistance involving upregulated genes in red (FGFR1, IGF1R, PI3K and 
MYC) and down regulated genes (green). (C) gene set enrichment analysis (GSEA) 
(FDR<0.05) revealed enrichment of gene sets of proliferation,12 IGF1R activation17 and 
progenitor features in acquired resistant tumours.
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Sorafenib-resistant tumours exhibit enrichment of cells with cancer stem-like properties. (A) 
Sphere formation capacity for three groups of tumours: parental non-treated, sorafenib-
sensitive and sorafenib-resistant tumours. Ratio (ie, 1 in 65 refer to number of cells forming 
spheres out of all cells plated). (B) Limiting dilution tumour initiation assay after 
subcutaneous cell transplantation in NOD.Cg-Prkdcscid IL2rgtm1Wjl (NSG). Ratio (ie, 1 in 
164 refer to number of cells inoculated needed to develop a tumour in vivo). Differences 
between number of cells needed in acquired resistance group versus others are significant 
(p<0.001). (C) Expression of liver progenitor cell markers and vimentin in spheres derived 
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from sorafenib-acquired resistant tumours (empty bars) and non-treated tumours (dark bars). 
Data represent the mean expression value for a gene normalised to 1 (mean expression value 
of its corresponding parental non-treated cell line). Expression level is relative to the 
GAPDH gene. Bars indicate SD. (D) Immunocytochemical analysis of progenitor cell 
markers in sorafenib-resistant tumour cells and parental. T-ICs, tumour-initiating cells.
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Cells from sorafenib-acquired resistant tumours are sensitive to IGF and FGF inhibition. (A) 
Heat map showing 342 differentially expressed genes between sorafenib-acquired resistant 
spheres and parental non-treated spheres (≥1.5-fold, FDR<0.05). GSEA shows significant 
enrichment of signatures of progenitor features, proliferation and IGF1R signalling in 
sorafenib-acquired resistant spheres (FDR<0.05). (B) Parental cells present significant 
decrease of cell viability on sorafenib treatment compared with sorafenib-acquired resistant 
cells. (C) Upregulation of IGF1R, FGFR1 and downstream protein kinase B (AKT) 
signalling in sorafenib-acquired resistant cells and Huh7 parental cells. (D) Cell viability in 
sorafenib-acquired resistant and parental cells, after transient transfection with siRNA 
against IGF1R or FGFR1 alone or in combination with sorafenib. (E) Cell viability of 
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sorafenib-acquired resistant cells and parental cells treated with sorafenib, IGF1R inhibitor 
(linsitinib (5 μM)) FGFR inhibitors (brivanib (5 μM) and BGJ398 (5 μM)) and 
combinations. Results are the mean of at least three independent experiments assayed in 
triplicate. Bars depict the SDs. Statistical significance is set at p<0.05.
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Assessment of IGF1R and/or FGFR1 signalling status in hepatocellular carcinoma (HCC)-
resistant cell lines. Expression/activation of IGF1R and FGFR1 and downstream signalling 
pathways (left panel), cell viability in the presence of sorafenib (central panel) and treatment 
with linsitinib, brivanib, or BGJ398 as single agents or in combination with sorafenib (right 
panel) were evaluated in (A) Huh6 parental and resistant cells lines and (B) Hep3B parental 
and resistant cells lines. Results are represented as the mean of at least three independent 
experiments assayed in triplicate. Bars depict the SDs. Statistical significance is set at 
p<0.05.
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An FGF inhibitor delayed tumour growth after development of acquired resistance and 
inhibited FGFR1 activation and downstream signalling. (A) Tumour growth in acquired 
resistant tumours of mice randomised to receive brivanib or sorafenib therapy. Data 
represent mean±SD. (B) Kaplan–Meier survival curves comparing the two groups. (C) qRT-
PCR analysis of FGFR1 and IGFR1 mRNA levels in each experimental group. Acquired 
resistant tumours present significant upregulation of IGF1R and FGFR1. (D) Representative 
immunostaining assessing the activation status of FGFR1, IGF-1R, Extracellular Signal-
regulated Kinase-1 (ERK) and RPS6 in formalin-fixed paraffin-embedded (FFPE) sections 
from xenograft tumours of each experimental group.
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Gene signature of acquired resistance to sorafenib predicts poor survival of patients with 
resected hepatocellular carcinoma (HCC; n=442), including training (n=223) and validation 
sets (n=219). (A) Generation of a 175 gene signature based on the transcriptomic analysis of 
mice tumours resistant to sorafenib. (B) and (C) Around 15% of patients in the training and 
validation set harbour the 175 gene signature of sorafenib resistance, which is significantly 
associated to poor outcome.
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